Literature DB >> 18616782

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.

R Q Klein1, C A Bangert, M Costner, M K Connolly, A Tanikawa, J Okawa, M Rose, S S Fakharzadeh, D Fiorentino, L A Lee, R D Sontheimer, L Taylor, A B Troxel, V P Werth.   

Abstract

BACKGROUND: Reliable and validated measures of skin disease severity are needed for cutaneous dermatomyositis (DM). Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Dermatomyositis Skin Severity Index (DSSI) and Cutaneous Assessment Tool (CAT) skin indices have been developed as outcome instruments.
OBJECTIVES: We sought to demonstrate reliability and validity of the CDASI, and to compare the CDASI with other potential tools for use in measuring disease severity in cutaneous dermatomyositis. PATIENTS AND METHODS: CDASI has four activity and two damage measures, with scores from 0 to 148. DSSI assesses activity based on body surface area and severity on a scale of 0-72. CAT uses 21 activity and damage items, for a range of 0-175 for activity and 0-33 for damage. Ten dermatologists used the instruments to score the same 12-16 patients in one session. Global validation measures were administered to physicians and patients.
RESULTS: Global validation measures correlated with the three outcome instruments (P < 0.0001). CAT displayed lower inter- and intrarater reliability relative to the CDASI. All scales correlate better with physician than patient global skin measures.
CONCLUSIONS: It appears that the CDASI may be a useful outcome measure for studies of cutaneous DM. Further testing to compare responsiveness of all three measures is necessary.

Entities:  

Mesh:

Year:  2008        PMID: 18616782      PMCID: PMC2829655          DOI: 10.1111/j.1365-2133.2008.08711.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  14 in total

Review 1.  How reliable are assessments of clinical teaching? A review of the published instruments.

Authors:  Thomas J Beckman; Amit K Ghosh; David A Cook; Patricia J Erwin; Jayawant N Mandrekar
Journal:  J Gen Intern Med       Date:  2004-09       Impact factor: 5.128

2.  Reliability: on the reproducibility of assessment data.

Authors:  Steven M Downing
Journal:  Med Educ       Date:  2004-09       Impact factor: 6.251

3.  The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

Authors:  Joerg Albrecht; Lynne Taylor; Jesse A Berlin; Samuel Dulay; Gina Ang; Steven Fakharzadeh; Jonathan Kantor; Ellen Kim; Giuseppe Militello; Karen McGinnis; Stephen Richardson; James Treat; Carmela Vittorio; Abby Van Voorhees; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2005-11       Impact factor: 8.551

4.  Is a simple generic index of dermatologic disease severity an attainable goal?

Authors:  H C Williams
Journal:  Arch Dermatol       Date:  1997-11

5.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 6.  Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis.

Authors:  R D Sontheimer
Journal:  Curr Opin Rheumatol       Date:  1999-11       Impact factor: 5.006

7.  Responsiveness and sensitivity to change of SLE disease activity measures.

Authors:  M Corzillius; P Fortin; G Stucki
Journal:  Lupus       Date:  1999       Impact factor: 2.911

Review 8.  Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects.

Authors:  Richard D Sontheimer
Journal:  Dermatol Clin       Date:  2002-07       Impact factor: 3.478

9.  Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests.

Authors:  P R Fortin; M Abrahamowicz; D Danoff
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

10.  Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis.

Authors:  Adam M Huber; Elizabeth M Dugan; Peter A Lachenbruch; Brian M Feldman; Maria D Perez; Lawrence S Zemel; Carol B Lindsley; Robert M Rennebohm; Carol A Wallace; Murray H Passo; Ann M Reed; Suzanne L Bowyer; Susan H Ballinger; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2008-02-15
View more
  38 in total

Review 1.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

2.  Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Joyce Okawa; Lynne Taylor; Victoria P Werth
Journal:  Arch Dermatol       Date:  2010-07

Review 3.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

4.  Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.

Authors:  J Tiao; R Feng; E M Berger; J F Brandsema; C C Coughlin; N Khan; E A Kichula; M A Lerman; S Lvovich; P J McMahon; L G Rider; A I Rubin; L V Scalzi; D M Smith; A J Taxter; J R Treat; R P Williams; S W Yum; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2017-07-31       Impact factor: 9.302

5.  Quality of life in dermatomyositis.

Authors:  Renato Goreshi; Monika Chock; Kristen Foering; Rui Feng; Joyce Okawa; Matt Rose; David Fiorentino; Victoria Werth
Journal:  J Am Acad Dermatol       Date:  2011-07-01       Impact factor: 11.527

6.  Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.

Authors:  C O Anyanwu; D F Fiorentino; L Chung; C Dzuong; Y Wang; J Okawa; K Carr; K J Propert; V P Werth
Journal:  Br J Dermatol       Date:  2015-08-11       Impact factor: 9.302

7.  Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.

Authors:  Renato Goreshi; Joyce Okawa; Matt Rose; Rui Feng; Lela A Lee; Christopher B Hansen; Carolyn A Bangert; M Kari Connolly; Mark D Davis; Jeff P Callen; Nicole M Fett; Steven S Fakharzadeh; Jennie T Clarke; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

8.  The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Suzanne Li; Kathleen M O'Neil; Elena Pope; Gloria C Higgins; Marilynn Punaro; Egla C Rabinovich; Margalit Rosenkranz; Daniel A Kietz; Paul Rosen; Steven J Spalding; Teresa R Hennon; Kathryn S Torok; Elaine Cassidy; Thomas A Medsger
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

9.  Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

Authors:  Paige W Wolstencroft; Lorinda Chung; Shufeng Li; Livia Casciola-Rosen; David F Fiorentino
Journal:  JAMA Dermatol       Date:  2018-01-01       Impact factor: 10.282

10.  Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.

Authors:  Misha Rosenbach; Howa Yeung; Emily Y Chu; Ellen J Kim; Aimee S Payne; Junko Takeshita; Carmela C Vittorio; Karolyn A Wanat; Victoria P Werth; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.